Patent intelligence · EP
EP 4529925
CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN
CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN
Patent details — EP 4529925
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Apr 2, 2025
- Expiration
- Mar 28, 2045
- Applicant
- CASSIOPEA S P A [IT]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 573 A I, A61K/31573, A61K/4706
Quick answer
EP 4529925 (CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Apr 2, 2025. Expires Mar 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CASSIOPEA S P A [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 573 A I, A61K/31573, A61K/4706, A61K/4710, A61K/4714
More from CASSIOPEA S P A [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026087531
FORMULATIONS DE CLASCOTÉRONE ET LEURS MÉTHODES D'UTILISATION
granted -
WO 2026057588
POLYTHÉRAPIE À BASE DE CLASCOTÉRONE ET DE MINOXIDIL POUR LE TRAITEMENT DE LA PERTE DES CHEVEUX
granted -
WO 2025172818
POLYTHÉRAPIE À BASE DE PYRILUTAMIDE
granted -
WO 2025125508
COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ
granted -
AR 132316
TRATAMIENTO COMBINADO CON CLASCOTERONA Y MINOXIDIL
granted -
WO 2025068281
CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES
granted -
US 2018169113
HIGH CONCENTRATION FORMULATION
granted
Frequently asked questions
What is US patent 4529925?
EP 4529925 (CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Apr 2, 2025. Expires Mar 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4529925?
CASSIOPEA S P A [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does EP 4529925 expire?
Our index shows an expiration date of Mar 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.